Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:TLRY News 8 October 2025 - 9 January 2026

Tilray Brands (TLRY) stock jumps in premarket after record $218 mln quarter and net cash turn

Tilray Brands (TLRY) stock jumps in premarket after record $218 mln quarter and net cash turn

Tilray shares jumped nearly 9% to $9.95 in premarket trading after reporting fiscal Q2 revenue of $217.5 million and a narrowed net loss of $43.5 million. The company reaffirmed its full-year adjusted profit target and said it moved to a net cash position. Gross margin slipped, and craft beer sales remained under pressure. Traders are watching if the gains hold at the open.
9 January 2026
··
Tilray Brands (TLRY) Stock News Today: Cannabis Rescheduling, Earnings Date, Reverse Split, and Analyst Forecasts (Dec. 24, 2025)

Tilray Brands (TLRY) Stock News Today: Cannabis Rescheduling, Earnings Date, Reverse Split, and Analyst Forecasts (Dec. 24, 2025)

Tilray Brands, Inc. (NASDAQ: TLRY) has spent December doing what cannabis stocks do best: moving fast, arguing loudly with gravity, and reacting to headlines like they’re caffeine. As of Wednesday, December 24, 2025, TLRY is trading around $10.53. The reason investors keep refreshing their screens is simple: U.S. federal cannabis policy may be shifting in a meaningful (but not instantly transformative) way. President Donald Trump signed an executive order on December 18, 2025 directing the process to reclassify marijuana from Schedule I to Schedule III, a move that could eventually reduce tax burdens and ease certain business constraints across the
24 December 2025
··
Tilray Brands (TLRY) Stock News Today: Trump Cannabis Rescheduling Reports Fuel Volatility, Fresh Forecasts and Key Levels (Dec. 17, 2025)

Tilray Brands (TLRY) Stock News Today: Trump Cannabis Rescheduling Reports Fuel Volatility, Fresh Forecasts and Key Levels (Dec. 17, 2025)

Tilray Brands, Inc. (NASDAQ: TLRY) stock is back in the spotlight on December 17, 2025, as cannabis stocks react—again—to fast-moving headlines around potential U.S. federal marijuana rescheduling. In the latest session, TLRY traded around $13.94, up roughly 27% on the day, after swinging between about $10.32 and $14.54—a reminder that Tilray remains one of the market’s most headline-sensitive, momentum-driven names. So what changed this time? A cluster of reports and follow-on commentary about President Donald Trump and a possible executive order aimed at reclassifying marijuana—paired with the stock’s own structural catalysts (notably its recent 1-for-10 reverse split)—is amplifying both upside
17 December 2025
···
Tilray Brands (TLRY) Stock News Today: Cannabis Rally Cools as Trump Schedule III Speculation Fuels Volatility

Tilray Brands (TLRY) Stock News Today: Cannabis Rally Cools as Trump Schedule III Speculation Fuels Volatility

December 15, 2025 Tilray Brands, Inc. (NASDAQ: TLRY) is back in the spotlight on December 15 after one of its biggest momentum bursts in years—followed by an equally fast reality check. The stock’s latest swing is being driven less by quarterly fundamentals and more by a single macro catalyst: growing (but still unconfirmed) expectations that President Donald Trump could move to ease federal marijuana restrictions by pushing a reclassification of cannabis to Schedule III. That policy headline helped ignite a sector-wide surge late last week. On Monday, however, the rally showed clear signs of fatigue as uncertainty over timing, scope,
15 December 2025
··
Tilray Stock Surges as Trump Schedule III Buzz Collides With New Vape Launch and Reverse Split Fallout

Tilray Stock Surges as Trump Schedule III Buzz Collides With New Vape Launch and Reverse Split Fallout

Tilray Brands (TLRY) is back at the center of the cannabis market’s biggest catalyst in years: growing expectations that President Donald Trump could move to ease federal marijuana restrictions by pushing a reclassification of cannabis to Schedule III. On Monday, December 15, 2025, the optimism spilled into global trading, with cannabis names extending last week’s explosive rally as investors tried to price what a Schedule III world could mean for taxes, banking access, and institutional participation. Reuters+1 But Tilray’s move isn’t just about Washington. The company is also coming off a 1-for-10 reverse stock split and fresh product momentum tied
15 December 2025
····
Tilray Brands (TLRY) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Tilray Brands (TLRY) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) is back in the spotlight heading into Monday’s U.S. market open (Dec. 15, 2025) after a policy-driven surge that reminded investors why cannabis-linked equities can move fast—often on headlines more than fundamentals. In Friday’s regular session (Dec. 12), TLRY closed at $12.15, up about 44% on the day, after trading in a wide $10.32–$13.85 range on ~84.2 million shares. Nasdaq Here’s what matters most before the bell: the federal-policy catalyst behind the move, the “post–reverse split” reality that can distort charts and targets, what Tilray’s latest financials say about the business today, and
14 December 2025
···
Tilray Brands (TLRY) Stock Jumps on Marijuana Rescheduling Buzz: This Week’s Move, Latest News, and Week-Ahead Outlook (Updated Dec. 12, 2025)

Tilray Brands (TLRY) Stock Jumps on Marijuana Rescheduling Buzz: This Week’s Move, Latest News, and Week-Ahead Outlook (Updated Dec. 12, 2025)

Updated: Friday, Dec. 12, 2025 (after U.S. market close)Meta description: Tilray (TLRY) surged this week as cannabis stocks spiked on reports Trump may push marijuana rescheduling. Here’s what happened and what to watch next week. Tilray Brands, Inc. (NASDAQ: TLRY) delivered one of the cannabis sector’s most dramatic weekly moves, culminating in a surge on Friday, December 12, as traders reacted to fresh reporting that President Donald Trump could soon take steps aimed at loosening federal marijuana restrictions. By the close on Dec. 12, TLRY finished at $12.15, up 44.13% on the day, after trading between $10.28 and $12.41. Volume
13 December 2025
··
Top Stock Gainers Today (Dec. 12, 2025): Cannabis Stocks TLRY, CGC Rally on Rescheduling Buzz; Rivian and Lululemon Lead Big-Cap Winners

Top Stock Gainers Today (Dec. 12, 2025): Cannabis Stocks TLRY, CGC Rally on Rescheduling Buzz; Rivian and Lululemon Lead Big-Cap Winners

Here are the top gainers in the U.S. stock market on Dec. 12, 2025—plus the news, analyst takes, and after-hours movers investors are watching. NEW YORK — Dec. 12, 2025 (Updated: 6:00 p.m. ET) Wall Street finished a choppy Friday with a familiar tug-of-war: mega-cap tech weakness pulling the major indexes lower, while pockets of the market lit up with explosive upside. The S&P 500 slid 1.1% to 6,827.41, the Nasdaq Composite fell 1.7% to 23,195.17, and the Dow Jones Industrial Average declined 0.5% to 48,458.05. Tech-heavy pressure showed up in names tied to the AI trade—Broadcom dropped 11.4%, Nvidia fell 3.3%, and Oracle slid 4.5%—even as the 10-year Treasury yield edged
13 December 2025
···
Top Stock Gainers Today (Dec. 12, 2025, 12:30 p.m. ET): cbdMD, Canopy Growth, Tilray Lead a Cannabis-Fueled Rally

Top Stock Gainers Today (Dec. 12, 2025, 12:30 p.m. ET): cbdMD, Canopy Growth, Tilray Lead a Cannabis-Fueled Rally

Here are the biggest US stock market gainers at midday on Dec. 12, 2025—plus what’s driving the moves, from cannabis policy headlines to earnings reports and SEC filings. StockAnalysis+2Reuters+2 At 12:30 p.m. ET on Friday, December 12, 2025, the US stock market is showing a familiar split screen: broad indexes are lower, led by weakness in tech and semiconductors, while a handful of headline-driven pockets—especially cannabis-related names and a few earnings movers—are posting outsized gains. On a percentage basis across US-listed stocks, many of the day’s top gainers are small-cap and micro-cap companies, where relatively modest flows (and, at times, trading halts or low liquidity) can translate
12 December 2025
····
Tilray Brands (TLRY) Stock Jumps on Trump Marijuana Rescheduling Report: Latest News, Forecasts, and Analyst Views (Dec. 12, 2025)

Tilray Brands (TLRY) Stock Jumps on Trump Marijuana Rescheduling Report: Latest News, Forecasts, and Analyst Views (Dec. 12, 2025)

Tilray Brands (NASDAQ: TLRY) is surging as cannabis stocks rally on fresh U.S. rescheduling headlines. Here’s what’s driving TLRY, what analysts forecast, and what to watch next. Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) is back in the spotlight on Friday, December 12, 2025, after a sharp move higher in extended-hours trading and premarket action alongside a broader rally in cannabis-linked equities. The immediate catalyst is political: a report that President Donald Trump is expected to push the federal government to loosen marijuana restrictions by directing agencies toward reclassifying marijuana as a Schedule III substance—a shift that could materially change
12 December 2025
···
US Stock Market Premarket Top Gainers Today (Dec. 12, 2025): Lululemon Surges, Cannabis Stocks Rally, Mitek and Quanex Jump

US Stock Market Premarket Top Gainers Today (Dec. 12, 2025): Lululemon Surges, Cannabis Stocks Rally, Mitek and Quanex Jump

Updated: Friday, December 12, 2025 — 6:00 a.m. ET SEO summary: Here are the biggest US stock market premarket gainers today (NYSE/Nasdaq) and the news driving them, including Lululemon’s earnings and CEO transition, a cannabis-stock surge tied to marijuana rescheduling headlines, and earnings-driven jumps in Mitek and Quanex. Nasdaq+4StockAnalysis+4Reuters+4 US stock futures were mixed early Friday, with investors balancing a post-Fed backdrop against renewed questions around big-tech AI spending after Oracle’s latest move and broader positioning into year-end. Reuters Below is a detailed look at the top premarket gainers as of about 6:00 a.m. ET, plus the headlines, forecasts, and analyst takes circulating on 12/12/2025. Top premarket stock gainers right now (as of ~6:00 a.m. ET) These are the leading percentage gainers in
12 December 2025
·············
Tilray Brands (TLRY) Soars After Reverse Stock Split and Cannabis Bill Hopes: Stock Forecast, Price Targets and 2026 Outlook

Tilray Brands (TLRY) Soars After Reverse Stock Split and Cannabis Bill Hopes: Stock Forecast, Price Targets and 2026 Outlook

As of December 10, 2025 Tilray stock rebounds 12% after brutal selling Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) just reminded investors how violently cannabis stocks can move. On Tuesday, December 9, 2025, TLRY jumped about 12.4% to close around $8.09, sharply outperforming a flat broader market. Trading volume topped 8.6 million shares, above the 50‑day average of roughly 7.8 million. Even after that rally, Tilray’s share price is still about 65% below its 52‑week high of $23.20, reached on October 9. MarketWatch+1 The surge followed weeks of heavy selling. On December 3, the stock fell 8.4% to $7.06, marking
10 December 2025
···
Tilray Brands (TLRY) Stock in December 2025: Reverse Split, 90% Rally and What the Latest Forecasts Really Say

Tilray Brands (TLRY) Stock in December 2025: Reverse Split, 90% Rally and What the Latest Forecasts Really Say

Data and commentary up to 7 December 2025, with a focus on developments and analysis published since 6 December 2025. This article is for information only and is not investment advice. A pivotal week for Tilray: reverse split, sell‑off and a 90% six‑month surge Tilray Brands Inc. (NASDAQ: TLRY) has just gone through one of the most consequential stretches in its recent history. After shareholders approved it back in June, the company finally executed a 1‑for‑10 reverse stock split, effective after the market close on 1 December 2025. Trading on a split‑adjusted basis began on 2 December, cutting the number
7 December 2025
·
Tilray Stock Skyrockets 300% on Cannabis Reform Hopes – Is TLRY’s Rally Sustainable?

Tilray Stock Skyrockets 300% on Cannabis Reform Hopes – Is TLRY’s Rally Sustainable?

Tilray’s Stock Price Soars on Reform Speculation Tilray’s stock has been on a tear in recent months, staging a stunning turnaround from penny-stock levels. The share price has quadrupled since early July – rising from well under $0.5 to around $1.7 by early October Nasdaq. Year-to-date, TLRY is up ~22% (as of Oct. 8) after being down over 20% mid-year Talkmarkets Hi Plainscoop. This rebound has rescued Tilray from the brink of a Nasdaq delisting – the company had even sought a compliance extension when its shares languished below $1 in the summer Hi Plainscoop. The rally hit overdrive in late September 2025. On September 29, Tilray
8 October 2025
··
Tilray Stock Skyrockets 300% on Cannabis Reform Hopes – Will TLRY’s Rally Last?

Tilray Stock Skyrockets 300% on Cannabis Reform Hopes – Will TLRY’s Rally Last?

Recent News & Stock Performance (October 2025) Tilray’s stock has been on a wild ride in early October 2025, propelled by a flurry of cannabis policy news. In the first week of October, TLRY jumped over 8% in one day (Oct 7) after an apparent breakthrough in U.S. marijuana reform sentimentnasdaq.comnasdaq.com. The trigger: several prominent Republican senators voiced unexpected support for easing federal cannabis laws, and former President Donald Trump – now in his second term – signaled openness to rescheduling marijuana. MarijuanaMoment reports that in late September, Trump shared a video touting CBD’s health benefits for seniors, and GOP
8 October 2025
··

Stock Market Today

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

7 February 2026
Bank of America shares rose 2.89% Friday to $56.53, tracking a rally in U.S. financial stocks as the Dow closed above 50,000. The bank will redeem its Series DD preferred stock and related depositary shares on March 10 at $1,000 per share. CEO Brian Moynihan donated 100,000 shares on Feb. 4, a regulatory filing showed. Key U.S. jobs and inflation data are due next week after delays.
Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

7 February 2026
Oracle shares jumped 4.65% to $142.82 Friday, ending an eight-day slide but remaining down 22% since Jan. 27. The company has set up a $20 billion at-the-market stock program and completed a $25 billion senior notes sale to fund cloud expansion. Oracle’s liabilities stood at $174.5 billion as of Nov. 30, 2025, before the new financing. Investors remain focused on dilution risks and the pace of capacity growth.
Go toTop